keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy and cardiotoxicity

keyword
https://www.readbyqxmd.com/read/29648903/cardiotoxicity-of-anthracycline-ant-treatment-in-children-with-malignant-tumors
#1
Huimin Hu, Weiling Zhang, Dongsheng Huang, Qingmiao Yang, Jing Li, Yanan Gao
OBJECTIVE: To investigate the cardiotoxicity indexes in children with malignant tumors after the administration of anthracycline (ANT) chemotherapy. MATERIALS AND METHODS: Data from 131 children with malignant tumors who were treated using ANT chemotherapy at our hospital from January 2011 to December 2015 were collected to analyze the serologic indexes (such as N-terminal pro-brain natriuretic peptide [NT-proBNP] and isoenzyme of creatine kinase [CK-MB]) and changes in corrected QT interval(QT-c) and left ventricular ejection fraction (LVEF) before and after treatment with different ANT cumulative doses...
April 12, 2018: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/29644219/management-of-chemotherapy-induced-left-ventricular-dysfunction-and-heart-failure-in-patients-with-cancer-while-undergoing-cancer-treatment-the-md-anderson-practice
#2
Anecita P Fadol
Chemotherapy-induced cardiotoxicity resulting in heart failure (HF) is one of the most dreaded complications of cancer therapy that can significantly impact morbidity and mortality. With a high prevalence of cardiovascular disease in cancer patients, the risk of developing HF is significantly increased. A new discipline of Onco-Cardiology has evolved to address the cardiovascular needs of patients with cancer, however, there is limited evidence-based data to guide clinical decision-making in the management of the cardiovascular complications of cancer therapy...
2018: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29643125/what-is-the-minimum-change-in-left-ventricular-ejection-fraction-which-can-be-measured-with-contrast-echocardiography
#3
Tan Suwatanaviroj, Weimin He, Edith Pituskin, Ian Paterson, Jonathan Choy, Harald Becher
BACKGROUND: There is limited data on what is the minimum change that can be detected in cancer patients undergoing treatment with cardiotoxic drugs who are referred for monitoring left ventricular (LV) function. OBJECTIVE: To assess variability in the measurement of LV volumes and ejection fraction (EF) in contrast echocardiography and to determine the minimum detectable difference (MDD) between two EF measurements that can be deemed significant. METHODS: A total of 150 patients were divided into three groups according to EF (EF <53%, 53%-60%, and >60%)...
April 11, 2018: Echo Research and Practice
https://www.readbyqxmd.com/read/29629020/diagnosis-treatment-and-prevention-of-cardiovascular-toxicity-related-to-anti-cancer-treatment-in-clinical-practice-an-opinion-paper-from-the-working-group-on-cardio-oncology-of-the-korean-society-of-echocardiography
#4
REVIEW
Hyungseop Kim, Woo-Baek Chung, Kyoung Im Cho, Bong-Joon Kim, Jeong-Sook Seo, Seong-Mi Park, Hak Jin Kim, Ju-Hee Lee, Eun Kyoung Kim, Ho-Joong Youn
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity...
March 2018: Journal of Cardiovascular Ultrasound
https://www.readbyqxmd.com/read/29620051/manipulation-free-cultures-of-human-ipsc-derived-cardiomyocytes-offer-a-novel-screening-method-for-cardiotoxicity
#5
Sheeja Rajasingh, Dona Greta Isai, Saheli Samanta, Zhi-Gang Zhou, Buddhadeb Dawn, William H Kinsey, Andras Czirok, Johnson Rajasingh
Induced pluripotent stem cell (iPSC)-based cardiac regenerative medicine requires the efficient generation, structural soundness and proper functioning of mature cardiomyocytes, derived from the patient's somatic cells. The most important functional property of cardiomyocytes is the ability to contract. Currently available methods routinely used to test and quantify cardiomyocyte function involve techniques that are labor-intensive, invasive, require sophisticated instruments or can adversely affect cell vitality...
April 5, 2018: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29616409/cardiotoxicity-in-hematological-diseases-are-the-tyrosine-kinase-inhibitors-imatinib-and-nilotinib-safe
#6
Ana Rita G Francisco, Daniela Alves, Cláudio David, Lurdes Guerra, Fausto J Pinto, Ana G Almeida
Chemotherapy-induced cardiotoxicity is a growing concern. The cardiotoxic impact of new drugs such as tyrosine kinase inhibitors is unknown, especially the ones used for chronic myeloid leukemia. We aim to evaluate nilotinib- and imatinib-induced cardiotoxicity. Single-center prospective study of consecutive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors was conducted during 2015. Patients underwent an initial clinical, laboratorial and echocardiographic evaluation, repeated after 1 year...
April 3, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29615646/bile-acids-increase-doxorubicin-sensitivity-in-abcc1-expressing-tumour-cells
#7
Simon Chewchuk, Tyler Boorman, Derek Edwardson, Amadeo M Parissenti
Tumour cells possess or acquire various mechanisms to circumvent the cytotoxic effects of chemotherapy drugs. One such mechanism involves the overexpression of ABC transporters that facilitate the extrusion of a variety of structurally distinct chemotherapy drugs from the cytoplasm into the extracellular space. While specific ABC transporter inhibitors have been developed, many affect other ABC transporters, particularly at elevated concentrations. It is also unclear whether they show clear efficacy for combatting drug resistance in cancer patients with minimal host toxicity...
April 3, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29610292/renin-angiotensin-system-inhibitors-to-mitigate-cancer-treatment-related-adverse-events
#8
Matthias Pinter, Wilhelmus J Kwanten, Rakesh K Jain
Treatment-related side effects are a major clinical problem in cancer treatment. They lead to reduced compliance to therapy as well as increased morbidity and mortality. Well-known are the sequelae of chemotherapy on the heart, especially in childhood cancer survivors. Therefore, measures to mitigate the adverse events of cancer therapy may improve health and quality of life in cancer patients, both in short and long term. The renin angiotensin system (RAS) affects all hallmarks of cancer, and blockage of the RAS is associated with an improved outcome in several cancer types...
April 2, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29608498/cardioprotection-in-the-modern-era-of-cancer-chemotherapy
#9
Anuradha Godishala, Shu Yang, Aarti Asnani
The current arsenal of cancer chemotherapy is broad and rapidly expanding, and includes conventional cytotoxic agents as well as targeted and immune-based therapies. As cancer survival rates have improved, the acute and latent cardiotoxicities of chemotherapy have emerged as important contributors to morbidity and mortality in cancer survivors. All chemotherapeutic agents have the potential for cardiac complications, with manifestations ranging from subclinical left ventricular dysfunction and asymptomatic QT prolongation, to congestive heart failure, myocardial ischemia, myocarditis, arrhythmia, and sudden cardiac death...
March 30, 2018: Cardiology in Review
https://www.readbyqxmd.com/read/29607467/new-no-and-h2s-releasing-doxorubicins-as-targeted-therapy-against-chemoresistance-in-castration-resistant-prostate-cancer-in-vitro-and-in-vivo-evaluations
#10
Elisabetta Bigagli, Cristina Luceri, Maria De Angioletti, Konstantin Chegaev, Mario D'Ambrosio, Chiara Riganti, Elena Gazzano, Simona Saponara, Mariangela Longini, Francesca Luceri, Lorenzo Cinci
Chemotherapy for castration-resistant prostate cancer (CRPC) is only temporarily effective due to the onset of chemoresistance. We investigated the efficacy of NO- and H2S-releasing doxorubicins (NitDox and H2SDox) in overcoming drug resistance and evaluated their safety. New and innovative NO- and H2 S-releasing doxorubicins (NitDox and H2 SDox) showed a good intracellular accumulation and high cytotoxic activity in vitro in an androgen-independent and doxorubicin-resistant DU-145 prostate cancer cell line...
April 2, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29603386/natural-history-of-myocardial-deformation-in-children-adolescents-and-young-adults-exposed-to-anthracyclines-systematic-review-and-meta-analysis
#11
Mirela Tuzovic, Pei-Tzu Wu, Samuel Kianmahd, Kim-Lien Nguyen
OBJECTIVE: Anthracyclines are widely used to treat solid and hematologic malignancies, but are known to cause cardiotoxicity. As more childhood cancer survivors reach adulthood due to improvements in oncologic treatments, they become susceptible to late and progressive anthracycline-induced cardiotoxicity. Nonetheless, diagnostic criteria for early detection of cardiac dysfunction are not well defined in children, adolescent, and young adults (CAYA, ages 1-40 years). We present a natural history of the changes in myocardial deformation in CAYA patients after anthracycline therapy...
March 30, 2018: Echocardiography
https://www.readbyqxmd.com/read/29593308/the-anti-cancer-multikinase-inhibitor-sorafenib-impairs-cardiac-contractility-by-reducing-phospholamban-phosphorylation-and-sarcoplasmic-calcium-transients
#12
Christopher Schneider, Markus Wallner, Ewald Kolesnik, Viktoria Herbst, Heinrich Mächler, Martin Pichler, Dirk von Lewinski, Simon Sedej, Peter P Rainer
Tyrosine-kinase inhibitors (TKIs) have revolutionized cancer therapy in recent years. Although more targeted than conventional chemotherapy, TKIs exhibit substantial cardiotoxicity, often manifesting as hypertension or heart failure. Here, we assessed myocyte intrinsic cardiotoxic effects of the TKI sorafenib and investigated underlying alterations of myocyte calcium homeostasis. We found that sorafenib reversibly decreased developed force in auxotonically contracting human myocardia (3 µM: -25 ± 4%, 10 µM: -29 ± 7%, 30 µM: -43 ± 12%, p < 0...
March 28, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29582557/five-year-results-of-a-phase-ii-trial-of-preoperative-5-fluorouracil-epirubicin-cyclophosphamide-followed-by-docetaxel-with-capecitabine-wtx-with-trastuzumab-in-her2-positive-patients-for-patients-with-stage-ii-or-iii-breast-cancer
#13
Frankie Ann Holmes, Beth A Hellerstedt, John E Pippen, Svetislava J Vukelja, Rufus P Collea, Darren M Kocs, Joanne L Blum, Kristi J McIntyre, Minal A Barve, Barry D Brooks, Cynthia R Osborne, Yunfei Wang, Lina Asmar, Joyce O'Shaughnessy
We aimed to increase pathologic complete response (pCR) in patients with invasive breast cancer by adding preoperative capecitabine to docetaxel following 5-fluorouracil, epirubicin, cyclophosphamide (FEC) (with trastuzumab for patients with HER2-positive disease) and to evaluate 5-year disease-free survival (DFS) associated with this preoperative regimen. Chemotherapy included four cycles of FEC100 (5-fluorouracil 500 mg/m2 , epirubicin 100 mg/m2 , cyclophosphamide 500 mg/m2 IV on Day 1 every 21 days) followed by 4 21-day cycles of docetaxel (35 mg/m2  days 1 and 8) concurrently with capecitabine (825 mg/m2 orally twice daily for 14 days followed by 7 days off) (wTX)...
March 26, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29581480/late-cardiovascular-morbidity-and-mortality-following-pediatric-allogeneic-hematopoietic-cell-transplantation
#14
Christine N Duncan, Ruta Brazauskas, Jiaxing Huang, Bronwen E Shaw, Navneet S Majhail, Bipin N Savani, Mary E D Flowers, Minoo Battiwalla, Kristen Beebe, Andrew C Dietz, Christopher C Dvorak, Roger Giller, David A Jacobsohn, Morris Kletzel, Paul L Martin, Eneida R Nemecek, Brandon Nuechterlein, Julie-An Talano, Michael A Pulsipher, K Scott Baker
We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24-230). 4.2% of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2%), cerebrovascular accident (0...
March 26, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29567630/anthracycline-induced-cardiotoxicity-a-multicenter-randomised-trial-comparing-two-strategies-for-guiding-prevention-with-enalapril-the-international-cardiooncology-society-one-trial
#15
Daniela Cardinale, Fabio Ciceri, Roberto Latini, Maria Grazia Franzosi, Maria Teresa Sandri, Maurizio Civelli, GianFranco Cucchi, Elisabetta Menatti, Maurizio Mangiavacchi, Raffaele Cavina, Enrico Barbieri, Stefania Gori, Alessandro Colombo, Giuseppe Curigliano, Michela Salvatici, Antonio Rizzo, Francesco Ghisoni, Alessandra Bianchi, Cristina Falci, Michele Aquilina, Andrea Rocca, Anna Monopoli, Carlo Milandri, Giuseppe Rossetti, Marco Bregni, Marco Sicuro, Alessandra Malossi, Daniele Nassiacos, Claudio Verusio, Monica Giordano, Lidia Staszewsky, Simona Barlera, Enrico B Nicolis, Michela Magnoli, Serge Masson, Carlo M Cipolla
BACKGROUND: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. METHODS: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals. Patients were randomly assigned to two strategies: enalapril in all patients started before chemotherapy (CT; 'prevention' arm), and enalapril started only in patients with an increase in troponin during or after CT ('troponin-triggered' arm)...
May 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29566148/co-administration-of-resveratrol-with-doxorubicin-in-young-mice-attenuates-detrimental-late-occurring-cardiovascular-changes
#16
Nobutoshi Matsumura, Beshay N Zordoky, Ian M Robertson, Shereen M Hamza, Nirmal Parajuli, Carrie-Lynn M Soltys, Donna L Beker, Marianne K Grant, Maria Razzoli, Alessandro Bartolomucci, Jason R B Dyck
AIMS: Doxorubicin (DOX) is among the most effective chemotherapies used in pediatric cancer patients. However, the clinical utility of DOX is offset by its well-known cardiotoxicity, which often does not appear until later in life. Since hypertension significantly increases the risk of late-onset heart failure in childhood cancer survivors, we investigated whether juvenile DOX exposure impairs the ability to adapt to angiotensin II (Ang II)-induced hypertension later in life as well as treatments that could prevent this...
March 16, 2018: Cardiovascular Research
https://www.readbyqxmd.com/read/29565770/vascular-and-autonomic-changes-in-adult-cancer-patients-receiving-anti-cancer-chemotherapy
#17
Jacob N Frye, Shelbi L Sutterfield, Jacob Troy Caldwell, Bradley Jon Behnke, Steven W Copp, Heather R Banister, Carl J Ade
BACKGROUND: Chemotherapy is associated with acute and long-term cardiotoxicity. To date, risk assessment has primarily focused on the heart; however, recent findings suggest that vascular and autonomic function may also be compromised. Whether this occurs during chemotherapy treatment remains unknown. Therefore, the present study evaluated carotid artery stiffness, cardiovagal baroreflex sensitivity (cBRS), and heart rate variability (HRV) in cancer patients currently being treated with adjuvant chemotherapy...
March 22, 2018: Journal of Applied Physiology
https://www.readbyqxmd.com/read/29563880/antineoplastic-drug-induced-cardiotoxicity-a-redox-perspective
#18
REVIEW
Gilda Varricchi, Pietro Ameri, Christian Cadeddu, Alessandra Ghigo, Rosalinda Madonna, Giancarlo Marone, Valentina Mercurio, Ines Monte, Giuseppina Novo, Paolo Parrella, Flora Pirozzi, Antonio Pecoraro, Paolo Spallarossa, Concetta Zito, Giuseppe Mercuro, Pasquale Pagliaro, Carlo G Tocchetti
Antineoplastic drugs can be associated with several side effects, including cardiovascular toxicity (CTX). Biochemical studies have identified multiple mechanisms of CTX. Chemoterapeutic agents can alter redox homeostasis by increasing the production of reactive oxygen species (ROS) and reactive nitrogen species RNS. Cellular sources of ROS/RNS are cardiomyocytes, endothelial cells, stromal and inflammatory cells in the heart. Mitochondria, peroxisomes and other subcellular components are central hubs that control redox homeostasis...
2018: Frontiers in Physiology
https://www.readbyqxmd.com/read/29557343/chemotherapy-related-cardiac-dysfunction-a-systematic-review-of-genetic-variants-modulating-individual-risk
#19
REVIEW
Marijke Linschoten, Arco J Teske, Maarten J Cramer, Elsken van der Wall, Folkert W Asselbergs
Chemotherapy-related cardiac dysfunction is a significant side effect of anticancer treatment. Risk stratification is based on clinical- and treatment-related risk factors that do not adequately explain individual susceptibility. The addition of genetic variants may improve risk assessment. We conducted a systematic literature search in PubMed and Embase, to identify studies investigating genetic risk factors for chemotherapy-related cardiac dysfunction. Included were articles describing genetic variants in humans altering susceptibility to chemotherapy-related cardiac dysfunction...
January 2018: Circulation. Genomic and precision medicine
https://www.readbyqxmd.com/read/29540327/carvedilol-for-prevention-of-chemotherapy-related-cardiotoxicity
#20
Monica Samuel Avila, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley Junior, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Vagner Oliveira Carvalho Rigaud, Marilia Higushi-Dos-Santos, Ludhmila Abrahão Hajjar, Roberto Kalil Filho, Paulo Marcelo Hoff, Marina Sahade, Marcela S M Ferrari, Romulo Leopoldo de Paula Costa, Max Senna Mano, Cecilia Beatriz Bittencourt Viana Cruz, Maria Cristina Abduch, Marco Stephan Lofrano Alves, Guilherme Veiga Guimaraes, Victor Sarli Issa, Marcio Sommer Bittencourt, Edimar Alcides Bocchi
BACKGROUND: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with β-blockers remains controversial. OBJECTIVE: The aim of this prospective, randomized, double-blind, placebo-controlled study was to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS: We randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m2 ) to receive carvedilol or placebo until chemotherapy completion...
March 3, 2018: Journal of the American College of Cardiology
keyword
keyword
83280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"